Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Matern Child Nutr ; 20(3): e13649, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38599819

RESUMEN

The main objective of this project was to compare in the field conditions two strategies of re-nutrition of children with moderate acute malnutrition (MAM) aged from 6 to 24 months, targeting the microbiota in comparison with a standard regimen. A three-arm, open-label, pragmatic randomised trial was conducted in four countries (Niger, CAR, Senegal and Madagascar). Children received for 12 weeks either fortified blended flour (FBF control) = arm 1, or FBF + azithromycin (oral suspension of 20 mg/kg/day daily given with a syringe) for the first 3 days at inclusion = arm 2 or mix FBF with inulin/fructo-oligosaccharides (6 g/day if age ≥12 months and 4 g if age <12 months) = arm 3. For each arm, children aged from 6 to 11 months received 100 g x 2 per day of flours and those aged from 12 to 24 months received 100 g × 3 per day of FBF. The primary endpoint was nutritional recovery, defined by reaching a weight-for-height z-score (WHZ) ≥ -1.5 within 12 weeks. Overall, 881 children were randomised (297, 290 and 294 in arm 1, arm 2 and arm 3, respectively). Three hundred and forty-four children were males (39%) and median/mean age were 14.6/14.4 months (SD = 4.9, IQR = 10.5-18.4). At inclusion, the three arms were comparable for all criteria, but differences were observed between countries. Overall, 44% (390/881) of the children recovered at week 12 from MAM, with no significant difference between the three arms (41.4%, 45.5% and 45.9%, in arm 1, arm 2 and arm 3, respectively, p = 0.47). This study did not support the true advantages of adding a prebiotic or antibiotic to flour. When using a threshold of WHZ ≥ -2 as an exploratory endpoint, significant differences were observed between the three arms, with higher success rates in arms with antibiotics or prebiotics compared to the control arm (66.9%, 66.0% and 55.2%, respectively, p = 0.005).


Asunto(s)
Harina , Alimentos Fortificados , Microbioma Gastrointestinal , Humanos , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/fisiología , Lactante , Femenino , Masculino , Preescolar , Azitromicina/administración & dosificación , Oligosacáridos/administración & dosificación , Inulina/administración & dosificación , Prebióticos/administración & dosificación , Antibacterianos/administración & dosificación
3.
Trials ; 19(1): 666, 2018 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-30514364

RESUMEN

BACKGROUND: The aim of this open-label, randomized controlled trial conducted in four African countries (Madagascar, Niger, Central African Republic, and Senegal) is to compare three strategies of renutrition for moderate acute malnutrition (MAM) in children based on modulation of the gut microbiota with enriched flours alone, enriched flours with prebiotics or enriched flours coupled with antibiotic treatment. METHODS: To be included, children aged between 6 months and 2 years are preselected based on mid-upper-arm circumference (MUAC) and are included based on a weight-for-height Z-score (WHZ) between - 3 and - 2 standard deviations (SD). As per current protocols, children receive renutrition treatment for 12 weeks and are assessed weekly to determine improvement. The primary endpoint is recovery, defined by a WHZ ≥ - 1.5 SD after 12 weeks of treatment. Data collected include clinical and socioeconomic characteristics, side effects, compliance and tolerance to interventions. Metagenomic analysis of gut microbiota is conducted at inclusion, 3 months, and 6 months. The cognitive development of children is evaluated in Senegal using only the Developmental Milestones Checklist II (DMC II) questionnaire at inclusion and at 3, 6, and 9 months. The data will be correlated with renutrition efficacy and metagenomic data. DISCUSSION: This study will provide new insights for the treatment of MAM, as well as original data on the modulation of gut microbiota during the renutrition process to support (or not) the microbiota hypothesis of malnutrition. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03474276 Last update 28 May 2018.


Asunto(s)
Antibacterianos/administración & dosificación , Azitromicina/administración & dosificación , Harina , Alimentos Fortificados , Microbioma Gastrointestinal/efectos de los fármacos , Trastornos de la Nutrición del Lactante/terapia , Fenómenos Fisiológicos Nutricionales del Lactante , Desnutrición/terapia , Estado Nutricional , Prebióticos/administración & dosificación , Enfermedad Aguda , África , Factores de Edad , Albendazol/administración & dosificación , Antibacterianos/efectos adversos , Antiparasitarios/administración & dosificación , Azitromicina/efectos adversos , Desarrollo Infantil , Preescolar , Femenino , Harina/efectos adversos , Alimentos Fortificados/efectos adversos , Humanos , Lactante , Trastornos de la Nutrición del Lactante/diagnóstico , Trastornos de la Nutrición del Lactante/microbiología , Trastornos de la Nutrición del Lactante/fisiopatología , Masculino , Desnutrición/diagnóstico , Desnutrición/microbiología , Desnutrición/fisiopatología , Estudios Multicéntricos como Asunto , Prebióticos/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...